RxDoctor Payments Data

Vernishia Hill Graham, MD

Family Medicine · Montgomery, ALNPI 1679864870

Payments from drug & device makers

$13,188in general payments, 2019–2025

Across 861 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$777
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$775
  • Amgen$763
  • Astellas Pharma US Inc$747
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,99499%
  • Education$1941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)130$1,473
Novo Nordisk72$1,108
Lilly USA, LLC60$777
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC50$775
Amgen45$763
Astellas Pharma US Inc34$747
Pfizer56$728
AstraZeneca37$656
Johnson & Johnson51$620
Otsuka America Pharmaceutical, Inc.30$549
Bayer24$420
GSK21$326
Novartis19$280
Takeda Pharmaceuticals U.S.A., Inc.11$250
Merck16$241
Mylan Specialty L.p.13$216
Boehringer Ingelheim15$212
Nestle Healthcare Nutrition Inc.10$196
Amarin Pharma, Inc.11$195
Lundbeck LLC8$165
Biohaven Pharmaceutical Holding Company Ltd.9$162
Sanofi-aventis U.S. LLC10$160
IBSA Pharma Inc.9$153
Arbor Pharmaceuticals, Inc.9$148
Axsome Therapeutics, Inc.8$143
Exact Sciences8$142
Sumitomo Pharma America, Inc.9$141
Biohaven Pharmaceuticals, Inc.7$130
Esperion Therapeutics, Inc.8$117
Abbott6$111
Idorsia Pharmaceuticals US Inc5$91
Adlon Therapeutics L.p.5$84
Antares Pharma, Inc.4$74
Ironwood Pharmaceuticals, Inc4$62
Corcept Therapeutics3$59
Supernus Pharmaceuticals, Inc.4$57
Aytu Biopharma, Inc.3$48
Dexcom, Inc.3$47
Neurocrine Biosciences, Inc.3$46
Evoke Pharma, Inc.2$36
Harmony Biosciences LLC2$35
Clarus Therapeutics Inc.2$32
Inspire Medical Systems, Inc.1$30
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$30
Assertio Therapeutics, Inc.2$27
Radius Health, Inc.1$26
Kowa Pharmaceuticals America, Inc.2$26
Seqirus USA Inc1$25
Ardelyx, Inc.1$22
Redhill Biopharma Inc.1$21
Tolmar, Inc.1$18
Viatris Specialty LLC1$18
Inogen, Inc.1$17
Scilex Pharmaceuticals Inc.1$16
E.r. Squibb & Sons, L.L.C.1$16
Phathom Pharmaceuticals, Inc.1$15
Eisai Inc.1$14
Currax Pharmaceuticals LLC1$14
Medicure Pharma Inc.1$14
Upsher-smith Laboratories LLC1$13

How this compares

$13,188 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$57,063
Medicare patients
182
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$106,353
JanuviaSitagliptin Phosphate60$91,234
JardianceEmpagliflozin82$90,252
EliquisApixaban71$82,838
FarxigaDapagliflozin Propanediol52$46,039
MounjaroTirzepatide38$45,050
GemtesaVibegron61$42,727
LinzessLinaclotide40$40,961
RybelsusSemaglutide22$30,595
Janumet XrSitagliptin Phos/Metformin Hcl31$29,656
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$28,929
MyrbetriqMirabegron26$27,624
Evenity (2 Syringes)Romosozumab-Aqqg11$27,428
TrulicityDulaglutide26$25,046
XareltoRivaroxaban16$24,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr, Janumet$241$139,523104 claims
Novo NordiskOzempic, Rybelsus$1,108$136,94898 claims
Boehringer IngelheimJardiance$212$90,25282 claims
PfizerEliquis$728$82,83871 claims
Lilly USA, LLCMounjaro, Trulicity$777$70,09664 claims
AstraZenecaFarxiga, Symbicort$656$50,01963 claims
AbbVieLinzess, Synthroid$1,473$44,81571 claims
Sumitomo Pharma America, Inc.Gemtesa$141$42,72761 claims
GSKTrelegy Ellipta, Breo Ellipta$326$35,29955 claims
Astellas Pharma US IncMyrbetriq$747$27,62426 claims
AmgenEvenity (2 Syringes)$763$27,42811 claims
Johnson & JohnsonXarelto$620$24,32116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →